Literature DB >> 12241663

Minimal residual low-grade gastric MALT-type lymphoma after eradication of Helicobacter pylori.

Wolfgang Fischbach1, Mariele Goebeler-Kolve, Petr Starostik, Axel Greiner, Hans Konrad Müller-Hermelink.   

Abstract

Helicobacter pylori eradication is the initial treatment of choice in localised low-grade gastric MALT (mucosa-associated lymphoid-tissue)-type lymphoma. We describe the natural course of seven patients who refused further oncological treatment for persistent lymphoma after successful eradication of H pylori. Despite persistent clonality, neither lymphoma progression nor high-grade transformation arose during a mean observation period of 34 (range 22-44) months. In view of the favourable course of these patients, a watch-and-wait strategy could be a valid approach to management of this disease.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12241663     DOI： 10.1016/S0140-6736(02)09711-8

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  10 in total

Review 1.  Molecular subtyping of gastric MALT lymphomas: implications for prognosis and management.

Authors:  M-Q Du; J C Atherton
Journal:  Gut       Date:  2006-06       Impact factor: 23.059

2.  Gastric MALT lymphoma with t(14;18)(q32;q21) involving IGH and BCL2 genes that responded to Helicobacter pylori eradication.

Authors:  Shotaro Nakamura; Hongtao Ye; Chris M Bacon; Hongxiang Liu; Alison Goatly; Takayuki Matsumoto; Hideki Koga; Junji Umeno; Yutaka Ohji; Takashi Yao; Tsukasa Nakahara; Mitsuo Iida; Ming-Qing Du
Journal:  J Clin Pathol       Date:  2007-10       Impact factor: 3.411

Review 3.  [Gastric lyphoma - still a result of surgery?].

Authors:  W Fischbach
Journal:  Chirurg       Date:  2006-06       Impact factor: 0.955

4.  Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series.

Authors:  W Fischbach; M-E Goebeler-Kolve; B Dragosics; A Greiner; M Stolte
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

Review 5.  Therapy of gastric mucosa associated lymphoid tissue lymphoma.

Authors:  Andrea Morgner; Renate Schmelz; Christian Thiede; Manfred Stolte; Stephan Miehlke
Journal:  World J Gastroenterol       Date:  2007-07-14       Impact factor: 5.742

Review 6.  The diminishing role of surgery in the treatment of gastric lymphoma.

Authors:  Sam S Yoon; Daniel G Coit; Carol S Portlock; Martin S Karpeh
Journal:  Ann Surg       Date:  2004-07       Impact factor: 12.969

Review 7.  Treatment of indolent non-Hodgkin's lymphoma with cladribine as single-agent therapy and in combination with mitoxantrone.

Authors:  James O Armitage; Kensei Tobinai; Dieter Hoelzer; Mathias J Rummel
Journal:  Int J Hematol       Date:  2004-05       Impact factor: 2.490

8.  Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be managed safely by a watch and wait strategy: experience from a large international series.

Authors:  W Fischbach; M E Goebeler; A Ruskone-Fourmestraux; T Wündisch; A Neubauer; M Raderer; A Savio
Journal:  Gut       Date:  2007-07-16       Impact factor: 23.059

9.  MALT Lymphomas.

Authors:  Sami N Malek; Amy J Hatfield; Ian W Flinn
Journal:  Curr Treat Options Oncol       Date:  2003-08

Review 10.  Gastrointestinal lymphoma.

Authors:  Philip J Bierman
Journal:  Curr Treat Options Oncol       Date:  2003-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.